Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Rezai

Showing results (61-70 of 61) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 61 results.
European Journal of Cancer (Oxford, England : 1990)|July 7, 2019
Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II 'proof-of-concept' iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) networkC Soussain, S Choquet, M Blonski, et al.
Pageof 7

Showing results (61-70 of 61) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 61 results.
European Journal of Cancer (Oxford, England : 1990)|July 7, 2019
Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II 'proof-of-concept' iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) networkC Soussain, S Choquet, M Blonski, et al.
Pageof 7